|
Real-time Estimate
Cboe BZX
07:28:34 18/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 782.72 USD | -0.85% |
|
+0.99% | +2.25% |
| Market Cap | 7.88TCr 6.87TCr 6.5TCr 5.9TCr 11TCr 7,55000Cr 11TCr 77TCr 30TCr 3,83700Cr 30TCr 29TCr 12,28300Cr | P/E 2026 * |
18.3x | P/E 2027 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise Value | 7.17TCr 6.24TCr 5.91TCr 5.37TCr 10TCr 6,86300Cr 10TCr 70TCr 27TCr 3,48800Cr 27TCr 26TCr 11,16500Cr | EV / Sales 2026 * |
4.23x | EV / Sales 2027 * | 3.72x |
| Free-Float |
71.06% | Yield 2026 * |
0.49% | Yield 2027 * | 0.56% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Xetra
| RGO | End-of-day quote | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Tradegate
| RGO | Real-time | |
|
London S.E.
| 0R2M | Delayed | |
|
Boerse Muenchen
| RGO | Real-time | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -1.05% | ||
| 1 week | +0.99% | ||
| Current month | -1.23% | ||
| 1 month | -2.59% | ||
| 3 months | +29.40% | ||
| 6 months | +6.07% | ||
| Current year | +2.25% |
| 1 week | 769.57 |  | 798.84 |
| 1 month | 769.57 | | 859.34 |
| Current year | 591.52 | | 859.34 |
| 1 year | 541 | | 859.34 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/09/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 02/09/26 | Exercice | Director | 1,200 | 0.0012% | ||
| 19/08/26 | Exercice | General Counsel | 33,583 | 0.0326% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | +0.99% | +31.83% | -4.28% | 7.88TCr | |
| -1.11% | +5.08% | -11.47% | -33.91% | 6.05TCr | |
| -1.32% | +8.86% | +515.80% | +50.49% | 6.31TCr | |
| -0.92% | -1.90% | -10.99% | +24.21% | 4.67TCr | |
| +0.34% | +1.80% | +2.85% | +152.47% | 4.57TCr | |
| -0.33% | +1.09% | +52.65% | -13.34% | 3.24TCr | |
| -0.18% | +5.42% | +48.90% | +115.17% | 2.59TCr | |
| +0.47% | +3.26% | -0.77% | +142.41% | 2.13TCr | |
| +0.43% | +2.60% | +63.21% | +104.08% | 1.58TCr | |
| -1.05% | -7.52% | +25.61% | +134.72% | 1.32TCr | |
| Average | -0.49% | +2.36% | +71.76% | +67.20% | 4.03TCr | |
| Weighted average by Cap. | -0.69% | +3.60% | +94.88% | +44.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.69TCr 1.47TCr 1.4TCr 1.27TCr 2.37TCr 1,62100Cr 2.38TCr 17TCr 6.43TCr 82TCr 6.36TCr 6.22TCr 2,63700Cr | 1.85TCr 1.61TCr 1.52TCr 1.38TCr 2.59TCr 1,77000Cr 2.6TCr 18TCr 7.02TCr 90TCr 6.94TCr 6.79TCr 2,88000Cr |
| Net income | 477.34Cr 415.76Cr 393.49Cr 357.51Cr 667.89Cr 46TCr 671.18Cr 4.69TCr 1.81TCr 23TCr 1.79TCr 1.75TCr 74TCr | 544.54Cr 474.29Cr 448.88Cr 407.84Cr 761.92Cr 52TCr 765.68Cr 5.35TCr 2.07TCr 27TCr 2.05TCr 2TCr 85TCr |
| Net Debt | -717.2Cr -624.68Cr -591.21Cr -537.16Cr -1TCr -69TCr -1.01TCr -7.04TCr -2.72TCr -35TCr -2.69TCr -2.63TCr -1,11700Cr | -1.01TCr -875.79Cr -828.87Cr -753.09Cr -1.41TCr -96TCr -1.41TCr -9.87TCr -3.82TCr -49TCr -3.78TCr -3.69TCr -1,56700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/26/18 | $786.14 | -0.42% | 1,35,364 |
| 17/26/17 | $789.45 | +1.92% | 7,02,816 |
| 16/26/16 | $774.61 | +0.06% | 3,82,945 |
| 15/26/15 | $774.11 | -2.47% | 5,40,837 |
| 14/26/14 | $793.74 | +1.57% | 5,91,295 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
